<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03640884</url>
  </required_header>
  <id_info>
    <org_study_id>Xueshuantong--V2.0</org_study_id>
    <nct_id>NCT03640884</nct_id>
  </id_info>
  <brief_title>Post-marketing Safety Surveillance of Xueshuantong-Injection : a Registry Study</brief_title>
  <official_title>Post-marketing Safety Surveillance of Xueshuantong-Injection : a Registry Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zhong Wang</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>China Academy of Chinese Medical Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This registry aims to monitor the safety of Xueshuantong Injection and to identify the
      potential risk factors for the adverse drug reactions.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Xueshuantong-Injection is a kind of natural compound injection with Panax notoginseng
      saponins(PNS). It's a popular drug for improving blood circulation that focusing on central
      retinal vein occlusion, stroke sequela, internal ophthalmopathy, hyphema and so on. However,
      more and more case reports about the adverse drug events of Panax notoginseng saponins have
      been reported in recent years. Therefore, this registry of Xueshuantong-Injection aims to
      monitor the safety and find the incidence of adverse drug reactions to
      Xueshuantong-Injection. Moreover, this registry is highly concerned on identifying the
      potential risk factors for the adverse drug reactions.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 18, 2019</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>2 Years</target_duration>
  <primary_outcome>
    <measure>The incidence of severe adverse reactions (SAR) of Xueshuantong-Injection</measure>
    <time_frame>2 years</time_frame>
    <description>A serious adverse reactions (SAR) is any untoward medical occurrence suspected to be medicinal product-related that at any dose: Results in death, is life-threatening, NOTE: The term &quot;life-threatening&quot; in the definition of &quot;serious&quot; refers to an event in which the patient was at risk of death at the time of the event; it does not refer to an event which hypothetically might have caused death if it were more severe. Requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, or Is a congenital anomaly/birth defect.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The incidence of adverse drug reactions (ADR) of Xueshuantong-Injection</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The incidence of adverse events （AE）of Xueshuantong-Injection</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The incidence of serious adverse events （SAE）of Xueshuantong-Injection</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The incidence of anaphylactic reaction of Xueshuantong-Injection</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The incidence of new ADRs of Xueshuantong-Injection</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The effective rate of Xueshuantong-Injection</measure>
    <time_frame>2 years</time_frame>
    <description>The proportion of the patients whose drug effect is considered as &quot;effective&quot; by investigator</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">30000</enrollment>
  <condition>Adverse Drug Event</condition>
  <condition>Adverse Drug Reactions</condition>
  <condition>Anaphylactic Reaction</condition>
  <condition>Severe Adverse Reactions</condition>
  <arm_group>
    <arm_group_label>Xueshuantong-Injection</arm_group_label>
    <description>Patients who received the Xueshuantong-Injection for treatment will be consecutive included in this registry. The investigators will record all the information about ADR, application of Xueshuantong-Injection and the combined medications, etc.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Xueshuantong-Injection</intervention_name>
    <description>Xueshuantong-Injection is a kind of natural compound injection extracted from Chinese herb Notoginseng. The major bioactive ingredient is panax notoginseng saponins.</description>
    <arm_group_label>Xueshuantong-Injection</arm_group_label>
    <other_name>Chenzhong</other_name>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Whole blood sample of the patient with severe adverse event
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients who received the Xueshuantong-Injection for treatment will be consecutive included
        in this registry
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients who use Xueshuantong-Injection in the monitoring departments of certain
             hospitals

        Exclusion Criteria:

          -  None
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhong Wang, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jinmin Liu, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dongfang Hospital Affiliated to Beijing University of traditional Chinese medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Zhong Wang, M.D.</last_name>
    <phone>8610-64093140</phone>
    <email>zhonw@vip.sina.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yanan Yu, M.D.</last_name>
    <phone>8610-64093140</phone>
    <email>pumpkinnaicha@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Jizhou City Hospital</name>
      <address>
        <city>Hengshui</city>
        <state>Hebei</state>
        <zip>053200</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhuci Li</last_name>
      <phone>86-13785829166</phone>
    </contact>
    <investigator>
      <last_name>Zhuci Li</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tongbai County People's Hospital</name>
      <address>
        <city>Nanyang</city>
        <state>Henan</state>
        <zip>474750</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yuqian Liu</last_name>
      <phone>86-13849716243</phone>
    </contact>
    <investigator>
      <last_name>Yuqian Liu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lingbao 3th People's Hospital</name>
      <address>
        <city>Sanmenxia</city>
        <state>Henan</state>
        <zip>472500</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wenhui Li</last_name>
      <phone>86-13569601991</phone>
    </contact>
    <investigator>
      <last_name>Wenhui Li</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>People's Hospital of Dancheng County</name>
      <address>
        <city>Zhoukou</city>
        <state>Henan</state>
        <zip>477150</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yuwang Yang</last_name>
      <phone>86-13333943936</phone>
    </contact>
    <investigator>
      <last_name>Yuwang Yang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dongxihu District People's Hospital</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430040</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hanqiao Wang</last_name>
      <phone>86-13707141018</phone>
    </contact>
    <investigator>
      <last_name>Hanqiao Wang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Donghai Country People's Hospital</name>
      <address>
        <city>Lianyungang</city>
        <state>Jiangsu</state>
        <zip>222300</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Liangliang Xia</last_name>
      <phone>86-15961321388</phone>
    </contact>
    <investigator>
      <last_name>Liangliang Xia</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>People's Hospital of Yichun City</name>
      <address>
        <city>Yichun</city>
        <state>Jiangxi</state>
        <zip>362201</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Huilin Leng</last_name>
      <phone>‭86-13870538072‬</phone>
    </contact>
    <investigator>
      <last_name>Huilin Leng</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Central Hospital of Wafangdian City</name>
      <address>
        <city>Dalian</city>
        <state>Liaoning</state>
        <zip>116300</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Qiang Zhao</last_name>
      <phone>86-15542661833</phone>
      <email>ywk85603813@163.com</email>
    </contact>
    <investigator>
      <last_name>Qiang Zhao</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lingyuan City Central Hospital</name>
      <address>
        <city>Lingyuan</city>
        <state>Liaoning</state>
        <zip>222500</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shuying Bai</last_name>
      <phone>86-13842101618</phone>
    </contact>
    <investigator>
      <last_name>Shuying Bai</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chinse Medical Hospital of Yangxin County</name>
      <address>
        <city>Binzhou</city>
        <state>Shandong</state>
        <zip>251800</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bingyi Qin</last_name>
      <phone>86-15206898878</phone>
    </contact>
    <investigator>
      <last_name>Bingyi Qin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Weihai Wendeng District People's Hospital</name>
      <address>
        <city>Weihai</city>
        <state>Shandong</state>
        <zip>264422</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jinguo Zhao</last_name>
      <phone>86-13561852177</phone>
    </contact>
    <investigator>
      <last_name>Jinguo Zhao</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Yangcheng County People's Hospital</name>
      <address>
        <city>Jincheng</city>
        <state>Shanxi</state>
        <zip>048100</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wangtai Cheng</last_name>
      <phone>86-13934060268</phone>
    </contact>
    <investigator>
      <last_name>Wangtai Cheng</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lingshi Country People's Hospital</name>
      <address>
        <city>Jinzhong</city>
        <state>Shanxi</state>
        <zip>031300</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaoqin Wu</last_name>
      <phone>86-13834185284</phone>
    </contact>
    <investigator>
      <last_name>Xiaoqin Wu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shanxi Yuanping First People's Hospital</name>
      <address>
        <city>Yuanping</city>
        <state>Shanxi</state>
        <zip>034100</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yutian Zhang</last_name>
      <phone>86-13994126666</phone>
    </contact>
    <investigator>
      <last_name>Yutian Zhang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>August 17, 2018</study_first_submitted>
  <study_first_submitted_qc>August 19, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 21, 2018</study_first_posted>
  <last_update_submitted>December 17, 2019</last_update_submitted>
  <last_update_submitted_qc>December 17, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 18, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>China Academy of Chinese Medical Sciences</investigator_affiliation>
    <investigator_full_name>Zhong Wang</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anaphylaxis</mesh_term>
    <mesh_term>Drug-Related Side Effects and Adverse Reactions</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

